Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C

Rogers, Cindy J.; Romagosa, Ricardo; Vincek, Vladimir

doi:10.1016/j.jaad.2003.06.013

Cited by 35 publications

(31 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence of lung disease in IIS appears to be less than in typical sarcoidosis (70% versus 90%) whereas the incidence of skin involvement (60% versus 25%) appears to be higher [7,[12][13][14][15]. Cutaneous manifestations include subcutaneous nodules, sarcoid papules, scar infiltration, and erythema nodosum.…”

Section: Discussionmentioning

confidence: 98%

“…Interferon-induced sarcoidosis (IIS) has been reported previously with the use of standard interferon alfa but there is limited data with pegylated interferon, with a few reports of cutaneous and pulmonary sarcoidosis occurring [5][6][7][8][9][10][11][12][13][14][15][16]. There are no published reports of hepatic sarcoidosis developing with pegylated interferon alfa use.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatic Sarcoidosis Associated with Pegylated Interferon Alfa Therapy for Chronic Hepatitis C—Case Report and Review of Literature

2008

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Hepatic Sarcoidosis Associated with Pegylated Interferon Alfa Therapy for Chronic Hepatitis C—Case Report and Review of Literature

2008

View full text Add to dashboard Cite

“…12 It was also reported in association with IFN therapy with cutaneous involvement in nearly half of cases. 13 The diagnosis of sarcoidosis is based mainly on the demonstration of noncaseating granuloma on skin biopsy. One of the characteristic histologic findings in our patients was the superficial location of dermal granuloma in nonsystemic cases.…”

Section: Discussionmentioning

confidence: 99%

Cutaneous Granulomas Associated With Interferon Therapy

El‐Khalawany

Mohammad

Aboeldahab

et al. 2016

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Treatment with interferon (IFN) could be associated with variable cutaneous adverse reactions. The aim of this study was to describe the clinicopathological spectrum of cutaneous granulomas associated with IFN therapy and identify the causal relation between IFN therapy and granulomatous reactions. The study included 18 patients (16 males and 2 females) with an average age of 48 years. Clinically, most of the lesions were solitary (83.3%) and located on the face (44.4%) and/or trunk (38.9%). The lesions were commonly presented as nodules (33.3%) or plaques (27.8%) with a common size of 5-10 cm. Granulomatous reactions were localized to the injection site in 4 cases, distributed on other body areas (remote granuloma) in 11 cases, and associated with lung involvement (systemic granuloma) in 3 cases. Histologically, injection site granuloma showed suppurative reaction in 75% and sarcoidal reaction in 25%. Remote granuloma showed tuberculoid reaction in 27.3%, interstitial in 27.3%, and sarcoidal in 45.4%. Systemic granuloma showed sarcoidal reaction in all cases. After withdrawal of IFN, only 3 lesions showed spontaneous complete clearance, whereas most of the lesions (83.3%) showed only partial improvement. Our results suggested that IFN is not a causal agent of all associated cutaneous granulomas but it mostly provokes the appearance of granulomatous reactions in susceptible individuals. Findings that prove this concept include the formation of granuloma in body sites away from the injection site, the heterogeneous pattern of granuloma both clinically and histologically, and incomplete clearance of most of the lesions after withdrawal of IFN.

show abstract

“…The discontinuation of treatment or a decrease in the dose of interferon is generally followed by a gradual reduction of sarcoidosis, though in some cases symptom remission is observed despite the continuation of treatment [10][11][12]. Management, where necessary, ranges from the removal of isolated nodules to corticotherapy in patients with systemic manifestations of sarcoidosis or a prolonged disease course.…”

Section: Discussionmentioning

confidence: 99%

Interferon-induced cutaneous sarcoidosis in melanoma

Suárez-García

Pérez‐Gil²,

Pereira-Gallardo³

et al. 2009

Melanoma Research

View full text Add to dashboard Cite

Interferon-induced cutaneous sarcoidosis in the adjuvant treatment of melanoma is a rare side effect. We present the case of a patient who developed two histologically confirmed subcutaneous sarcoid nodules 15 months after starting adjuvant therapy with interferon for lymph node metastatic melanoma in which the primary tumor was not known. The extension study, coinciding with occurrence of the nodules, showed no systemic sarcoidosis. This therefore represents the second reported case of interferon-induced cutaneous sarcoidosis in melanoma therapy. As computed axial tomography-PET or other imaging techniques are unable to differentiate between the radiological signs of melanoma metastasis and sarcoidosis, histological evaluation of the granulomatous lesions is essential with a view to avoiding unnecessary treatments.

show abstract

Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C

Cited by 35 publications

References 5 publications

Hepatic Sarcoidosis Associated with Pegylated Interferon Alfa Therapy for Chronic Hepatitis C—Case Report and Review of Literature

Hepatic Sarcoidosis Associated with Pegylated Interferon Alfa Therapy for Chronic Hepatitis C—Case Report and Review of Literature

Cutaneous Granulomas Associated With Interferon Therapy

Interferon-induced cutaneous sarcoidosis in melanoma

Contact Info

Product

Resources

About